{{Rsnum
|rsid=10021308
|Gene=SORBS2
|Chromosome=4
|position=185795830
|Orientation=plus
|GMAF=0.4743
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SORBS2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 19.5 | 50.4 | 30.1
| HCB | 8.8 | 50.4 | 40.9
| JPT | 4.4 | 46.9 | 48.7
| YRI | 27.2 | 51.0 | 21.8
| ASW | 33.3 | 49.1 | 17.5
| CHB | 8.8 | 50.4 | 40.9
| CHD | 14.7 | 36.7 | 48.6
| GIH | 28.7 | 55.4 | 15.8
| LWK | 22.7 | 49.1 | 28.2
| MEX | 24.6 | 56.1 | 19.3
| MKK | 7.1 | 40.4 | 52.6
| TSI | 35.3 | 45.1 | 19.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10021308
|Name_s=
|Gene_s=SORBS2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00001. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109518
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10021308
|overall_frequency_n=64
|overall_frequency_d=128
|overall_frequency=0.5
|n_genomes=43
|n_genomes_annotated=0
|n_haplomes=54
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}